WO2001034172A3 - Methods and compositions for treating reward deficiency syndrome - Google Patents

Methods and compositions for treating reward deficiency syndrome Download PDF

Info

Publication number
WO2001034172A3
WO2001034172A3 PCT/US2000/030312 US0030312W WO0134172A3 WO 2001034172 A3 WO2001034172 A3 WO 2001034172A3 US 0030312 W US0030312 W US 0030312W WO 0134172 A3 WO0134172 A3 WO 0134172A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treating
methods
deficiency syndrome
reward deficiency
Prior art date
Application number
PCT/US2000/030312
Other languages
French (fr)
Other versions
WO2001034172A2 (en
Inventor
Gregory M Sullivan
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Priority to AU13598/01A priority Critical patent/AU1359801A/en
Publication of WO2001034172A2 publication Critical patent/WO2001034172A2/en
Publication of WO2001034172A3 publication Critical patent/WO2001034172A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to methods and compositions for treating Reward Deficiency Syndrome (RDS) using a therapeutically effective amount of a monoamine oxidase B inhibitor. The present invention also relates to compositions for treating RDS comprising selegiline in very low dose.
PCT/US2000/030312 1999-11-05 2000-11-03 Methods and compositions for treating reward deficiency syndrome WO2001034172A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13598/01A AU1359801A (en) 1999-11-05 2000-11-03 Methods and compositions for treating reward deficiency syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16370899P 1999-11-05 1999-11-05
US60/163,708 1999-11-05

Publications (2)

Publication Number Publication Date
WO2001034172A2 WO2001034172A2 (en) 2001-05-17
WO2001034172A3 true WO2001034172A3 (en) 2001-10-25

Family

ID=22591235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030312 WO2001034172A2 (en) 1999-11-05 2000-11-03 Methods and compositions for treating reward deficiency syndrome

Country Status (2)

Country Link
AU (1) AU1359801A (en)
WO (1) WO2001034172A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8595055B2 (en) 2001-03-27 2013-11-26 Points.Com Apparatus and method of facilitating the exchange of points between selected entities
US6660736B2 (en) 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
MXPA04010537A (en) 2002-04-26 2005-01-25 Hoffmann La Roche Isoquinoline derivatives.
CN100482638C (en) 2002-05-29 2009-04-29 弗·哈夫曼-拉罗切有限公司 N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
US6846832B2 (en) 2002-08-07 2005-01-25 Hoffman-La Roche Inc. 2,3-dihydro-isoindol-1-one derivatives
PE20050077A1 (en) 2002-09-20 2005-03-01 Hoffmann La Roche DERIVATIVES OF 4-PYRROLIDINE-PHENYL-BENZYL-ETHER
ES2270154T3 (en) 2002-12-13 2007-04-01 F. Hoffmann-La Roche Ag DERIVATIVES OF 3H-QUINAZOLIN-4-ONA.
US7148362B2 (en) 2003-09-18 2006-12-12 Hoffmann-La Roche Inc. Process for the preparation of enantiopure pyrrolidin-2-one derivatives
CN100441188C (en) 2003-10-23 2008-12-10 弗·哈夫曼-拉罗切有限公司 Benzazepine derivatives as MAO-B inhibitors
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
JP4427578B2 (en) 2004-06-23 2010-03-10 エフ．ホフマン−ラ ロシュ アーゲー New MAO-B inhibitor
RU2378270C2 (en) 2004-08-02 2010-01-10 Ф. Хоффманн-Ля Рош Аг Benzyloxy-derivatives as monoamine oxidase b inhibitors
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
DE602006003879D1 (en) 2005-03-15 2009-01-08 Hoffmann La Roche PROCESS FOR THE PREPARATION OF ENANTIOMERINE PURE 4-PYRROLIDINOPHENYL-BENZYL ETHER DERIVATIVES
CN101032474B (en) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 Rasagiline transparent patch for curing and preventing neurological diseases and the preparing method thereof
EP3230255B1 (en) * 2014-12-09 2020-03-18 Ezekiel Golan Binge behavior regulators
US11528924B2 (en) 2014-12-09 2022-12-20 Clearmind Medicine, Inc. Alcoholic beverage substitutes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812481A (en) * 1986-04-16 1989-03-14 Degussa Aktiengesellschaft Synergistic combination of amantadiene and selegiline
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
US5721258A (en) * 1993-08-17 1998-02-24 Asta Medica Aktiengesellschaft Primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812481A (en) * 1986-04-16 1989-03-14 Degussa Aktiengesellschaft Synergistic combination of amantadiene and selegiline
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
US5721258A (en) * 1993-08-17 1998-02-24 Asta Medica Aktiengesellschaft Primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases

Also Published As

Publication number Publication date
AU1359801A (en) 2001-06-06
WO2001034172A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
WO2001034172A3 (en) Methods and compositions for treating reward deficiency syndrome
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
WO1999005096A3 (en) Urokinase inhibitors
YU5003A (en) New pharmaceutical composition
EP1378240A3 (en) Pharmaceutical compositions comprising arsenic for the treatment of multiple myeloma
ZA99913B (en) Alteration of amino acid compositions in seeds.
TR199902802T2 (en) Probucol monoesters for the treatment of cardiovascular diseases and inflammatory diseases.
SE9803710L (en) Use of certain substances for the treatment of nerve root damage
HK1056878A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
SI0814789T2 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
NZ531404A (en) Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
MXPA04002565A (en) Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation.
SE9603725D0 (en) New teatment
AU2001268233A1 (en) Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
WO2001030334A3 (en) 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation
WO2005041886A3 (en) Methods for generating or increasing revenues related to pain inhibitor commerce
IL130500A (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
WO2001088530A3 (en) Method for selecting enzyme inhibitors
WO2001000189A3 (en) Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments
ATE270113T1 (en) COMPOSITIONS FOR IMPROVED WOUND HEALING
DE69732784D1 (en) INHIBITION OF INVASIVE REMODULATION
WO1998047494A3 (en) Novel use of matrix metalloproteinase inhibitors
WO2002028398A1 (en) Compositions for treating diabetes
ZA991924B (en) Inhibitors of type 5 and type 3 17 beta-hydroxysteroid dehydrogenase and methods for their use.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase